Alector, Inc.
ALEC
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial forā¦ read more
Healthcare
Biotechnology
6 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$1.40
Price+0.72%
$0.01
1Y
Price
Market Cap
$140.301m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-1025.5%
EBITDA Margin-1063.4%
Net Profit Margin-997.6%
Free Cash Flow MarginRevenue
$69.048m
-31.3%
1y CAGR-18.4%
3y CAGR-22.6%
5y CAGREarnings
-$107.736m
+9.5%
1y CAGR+6.8%
3y CAGR-61.6%
5y CAGREPS
-$1.07
+13.0%
1y CAGR+12.6%
3y CAGR-55.5%
5y CAGRBook Value
$57.712m
$335.285m
Assets$277.573m
Liabilities$37.875m
DebtDebt to Assets
11.3%
-0.3x
Debt to EBITDAFree Cash Flow
-$197.582m
+14.5%
1y CAGR-224.2%
3y CAGR-195.2%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company